Simultaneous quantitative determination of remdesivir, dexamethasone, rosuvastatin, and atorvastatin in human plasma using HPLC-UV analysis

A new reversed-phase high-performance liquid chromatographic method was developed for the simultaneous determination and quantification of two clinically proven drugs in COVID-19 treatment – remdesivir and dexamethasone – and two 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors – rosuvastatin and atorvastatin – in human plasma by isocratic elution and ultraviolet detection. A mobile phase consisting of 0.1% trifluoroacetic acid in water and acetonitrile (60:40, v/v) was used in the proposed analytical procedure, and the chromatographic determination was performed on a Purospher® RP–18 column at room temperature. The developed method was validated for linearity in the range of 1–24 µg/ml, with correlation coefficients greater than 0.998. The percentage recovery of the analyzed drugs was 100.87, 99.71, 102.41, and 93.38% for remdesivir, dexamethasone, rosuvastatin, and atorvastatin, respectively. The developed, effective, and specific method is suitable for implementation in routine quality control and clinical laboratory practice.